scientific presentations

MGTA-117, an Anti-CD117 Antibody-Drug Conjugated With Amanitin, in Participants With Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia With Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings From a Phase 1/2 Study
Adobe PDFASH Annual Meeting Presentation, December 2022


The Pharmacokinetic and Pharmacodynamic Characterization of MGTA-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate for Targeted Conditioning Prior to Transplant, in Nonhuman Primates
Adobe PDFASH Annual Meeting Poster, December 2022


CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modifed CD34+ Cells in a Rhesus Gene Therapy Model
Adobe PDFASH Presentation, December 2021


Single Agent CD117-targeted Antibody Drug Conjugate in Combination with Lymphodepleting Antibodies Enables Allogeneic Hematopoietic Stem Cell Transplantation in Mice without Chemotherapy or Radiation
Adobe PDFASH Annual Meeting Poster, December 2021


A Novel Short Half-life Anti-Human CD117-Amanitin ADC Exhibits Dual HSCT Conditioning and Anti-Leukemia Activity and Extends Survival in Multiple Preclinical Models of AML
Adobe PDFEBMT Annual Meeting Poster, March 2021


A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Pre-clinical Models of Acute Myeloid Leukemia (AML) (Oral Abstract, #53)
Adobe PDFTCT Annual Meeting Presentation, February 2021


A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML) (Abstract #1044)
Adobe PDFASH Annual Meeting Poster, December 2020


A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #5)
Adobe PDFTCT Annual Meeting Presentation, February 2020


A Non-Genotoxic Anti-CD117 Antibody Drug Conjugate (ADC) Designed for Patient Conditioning Prior to Stem Cell Transplant and HSC-Based Gene Therapy Has a Broad Therapeutic Window Across Species (Abstract #44)
Adobe PDFTCT Annual Meeting Presentation, February 2020


A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #610)

Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model as a Single Agent (Poster #242)
Adobe PDFTCT Annual Meeting Presentation, February 2021


Reversing clonal hematopoiesis and associated atherosclerotic disease by targeted antibody-drug-conjugate (ADC) conditioning and transplant (Abstract #1843)
Adobe PDFASH Annual Meeting Presentation, December 2020


Single Agent CD45-targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model (Abstract #2330)
Adobe PDFASH Annual Meeting Presentation, December 2020


A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Ameliorate Disease in Preclinical Autoimmune Disease Models and Enable Auto HSCT (Abstract #0030)
Adobe PDFEBMT Annual Meeting Poster, Aug/Sept 2020


A CD45-targeted Antibody Drug Conjugate Enables Allogeneic Hematopoietic Stem Cell Transplantation as a Single Agent in Mice (Abstract #A174)
Adobe PDFEBMT Annual Meeting Poster, Aug/Sept 2020


A Novel Targeted Approach to Achieve Immune System Reset: A Single Dose of Magenta CD45-Targeted Antibody Drug Conjugate Enables Autologous HSCT and Ameliorates Disease in Murine Models of Autoimmune Disease (Abstract #3208)
Adobe PDFASH Annual Meeting Poster, December 2019


Administration of a CD45 Antibody Drug Conjugate As a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease (Abstract #120)

A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
Adobe PDFASH Annual Meeting Poster, December 2022


MGTA-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 study
Adobe PDFASH Annual Meeting Poster, December 2021


Phase 2 study of MGTA-145 + Plerixafor for Rapid and Reliable Hematopoietic Stem Cell (HSC) Mobilization for Autologous Stem Cell Transplant in Multiple Myeloma
Adobe PDFASCO 2021, June 2021


Phase 2 Study of MGTA-145 + Plerixafor for Rapid and Reliable Hematopoietic Stem Cell (HSC) Mobilization for Autologous Stem Cell Transplant in Multiple Myeloma (Abstract EP1224)
Adobe PDFEHA Congress 2021, June 2021


MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant
Adobe PDFEBMT 2021 Annual Meeting Presentation, March 2021


MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant (Oral Abstract, #35)
Adobe PDFTCT Annual Meeting Presentation, February 2021


MGTA-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells (Oral Abstract, #16)
Adobe PDFTCT Annual Meeting Presentation, February 2021


MGTA-145/Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells of CD46-Transgenic and Thalassemia Mice (Abstract #2602)
Adobe PDFASH Annual Meeting Poster, December 2020


MGTA-145, In Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant (Oral Abstract #184)
Adobe PDFASH Annual Meeting Presentation, December 2020


Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #A325)
Adobe PDFEBMT Annual Meeting Poster, Aug/Sept 2020


MGTA-145, in Combination with Plerixafor, Rapidly Mobilizes Large Numbers of HSCs in Humans That Can Be Gene Edited with CRISPR/Cas9 and Mediate Superior Engraftment to Standard-of-Care (Abstract #123)
Adobe PDFASGCT Annual Meeting Presentation, May 2020


MGTA-145/Plerixafor-Mediated HSC Mobilization Allows for Efficient In Vivo HSC Transduction and Stable Gene Marking in Murine Peripheral Blood Cells (Abstract #810)
Adobe PDFASGCT Annual Meeting Poster, May 2020


Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF (Abstract #73)
Adobe PDFTCT Annual Meeting Presentation, February 2020


Rapid and Robust Mobilization of CD34 + HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #1961)
Adobe PDFASH Annual Meeting Poster, December 2019